The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | Promising approaches for managing patients with MCL with prior BTKi exposure
Yasmin Karimi, MD, University of Michigan, Ann Arbor, MI, outlines promising approaches for managing patients with mantle cell lymphoma (MCL) who have previously been exposed to a BTK inhibitor (BTKi), including BCL-2 inhibitors such as venetoclax, bispecific antibodies, and re-challenging with an alternative BTKi. Dr Karimi emphasizes the need for data from randomized head-to-head trials to determine the best treatment option in this setting. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
